1. Targeting Novel RA Pathways Within the Cell: At the Cutting Edge of Therapy

2. Introduction/Background

3. JAK-STAT Pathway: Basic Operation

4. Discovery of the JAK-STAT Signaling Pathway

5. Complexity of Response to IFN Gamma: JAK/STAT Activation

6. JAK-STAT Pathway and Cytokine Signaling

7. Cell Communication

8. The JAK-STAT Pathway Is a Prime (and Primordial) Extra- and Intra-Cellular Communications Pathway

9. Evolutionary Conservation of the Physiologic Roles of the JAK-STAT Pathway: The Drosophila JAK/STAT Pathway

10. The Human Canonical Model of JAK-STAT Signaling

11. Cytokines, Factors, and Intracellular Signaling Components Implicated in the Pathogenesis of RA

12. Pathogenesis of RA: Triggers and Epigenetic and Post-Translational Disease-Related Modifications

13. Immune and Inflammatory Responses: Pathogenesis of Synovitis Characteristic of RA[a-c]

14. Cytokine Profiles That Subserve the Biology of Discrete Phases of the RA Disease Process

15. Many Cytokines and Growth Factors Converge on the JAK Signaling Pathway[a-c]

16. Cytokine Pathways and Blocking Agents: One Target at a Time[a-b]

17. The Biological Significance of Signaling Through Different JAK Combinations: Multiple Pathophysiologic Targets[a-d]

18. Elevated STAT3 Expression in Patients With Early RA

19. Stratifying Non- or Inadequate- Treatment Response in RA

20. Tofacitinib JAK 1 and JAK3 Inhibitor: Clinical Trial Results in RA

21. Baricitinib: Key Studies in RA Phase 3 Program and Their Characteristics

22. Topline Results for Baricitinib: RA-BEAM and RA-BUILD

23. RA-BEACON: Baricitinib in RA Patients With an Inadequate Response to TNF-Alpha Inhibitors

24. Patient-Reported Outcomes: RA-BEAM Phase 3 Trial of Baricitinib

25. Filgotinib: Results From the DARWIN 2 Trial

26. Summary and Conclusions

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)

30. Abbreviations (cont)